VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
GENI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
GENIGenius Sports Limited
$6.47$1.7B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. GENI
  4. Financial Ratios

Genius Sports Limited (GENI) Financial Ratios

Latest Ratios: P/E Ratio -14.7x · EV/EBITDA N/A · ROE -17.2%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

GENI Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$1.7B$2.8B$2.0B$1.4B$710M$1.1B$3.1B——
Enterprise Value$1.4B$2.6B$1.9B$1.3B$609M$925M$3.2B——
P/E Ratio →-14.70————————
P/S Ratio2.494.193.893.382.084.3720.98——
P/B Ratio2.283.883.472.441.231.6214.87——
P/FCF25.8243.50112.77——————
P/OCF19.2932.5024.2593.84——184.00——

P/E links to full P/E history page with 30-year chart

GENI EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—3.823.683.171.783.5221.52——
EV / EBITDA——134.13415.98——230.10——
EV / EBIT—————————
EV / FCF—39.62106.93——————

GENI Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin23.0%23.0%25.2%16.7%0.8%-81.2%23.8%22.1%40.9%
Operating Margin-15.6%-15.6%-11.5%-18.0%-53.6%-218.2%-14.0%-31.6%-19.7%
Net Profit Margin-16.7%-16.7%-12.3%-20.7%-53.3%-225.6%-20.3%-35.1%-28.9%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-17.2%-17.2%-11.0%-14.9%-28.3%-129.2%-46.7%-44.7%-9.7%
ROA-11.6%-11.6%-8.0%-11.0%-21.9%-92.8%-7.9%-10.9%-7.0%
ROIC-16.6%-16.6%-9.2%-11.6%-28.6%-110.8%-11.4%-19.1%-4.3%
ROCE-15.3%-15.3%-9.9%-12.4%-27.4%-110.3%-6.7%-11.0%-5.1%

GENI Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.040.040.010.030.040.000.44—0.24
Debt / EBITDA——0.544.67——6.64—996.21
Net Debt / Equity—-0.35-0.18-0.15-0.18-0.310.38—0.15
Net Debt / EBITDA——-7.32-27.18——5.80—617.86
Debt / FCF—-3.87-5.83—————5.55
Interest Coverage-17432.17-17432.17——-121.86-180.46-2.62-5.14—

Net cash position: cash ($281M) exceeds total debt ($30M)

GENI Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio1.561.561.431.341.382.120.720.711.67
Quick Ratio1.561.561.431.341.382.120.710.701.66
Cash Ratio0.800.800.550.550.721.460.140.150.95
Asset Turnover—0.590.640.530.440.300.380.310.24
Inventory Turnover1815.661815.66792.92991.271194.93898.43297.05317.83325.82
Days Sales Outstanding—102.3388.90103.2978.36107.4484.9886.0657.58

GENI Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————27.3%———
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield—————————
FCF Yield3.9%2.3%0.9%——————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%27.3%0.0%——
Shares Outstanding—$255M$230M$226M$199M$151M$179M$179M$261M

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Escalating Rights Cost Pressure

Market Pricing Reflects Growth Expectations

Based on current market data, GENI trades at a price-to-sales ratio of 2.38, which appears to price in aggressive top-line expansion while ignoring the lack of GAAP profitability, a valuation stance that warrants caution when compared to the more established, albeit slower-growing, industry peers.

The negative P/E ratio of -14.09 highlights that investors are currently valuing the company purely on its revenue growth trajectory rather than its ability to generate bottom-line earnings. This valuation approach assumes that the company will eventually achieve significant operating leverage, yet the current P/S multiple suggests the market remains skeptical of the timeline for that transition.

Capital Returns Remain Deeply Negative

As reported in recent financial statements, GENI's ROIC of -4.4% in 2026Q1 underscores a persistent inability to generate returns on invested capital that exceed the cost of funding, a trend that has remained stubbornly negative throughout the last ten quarters of aggressive rights acquisition.

The consistent decay in ROIC suggests that the capital deployed to secure exclusive data rights is not yet yielding sufficient incremental revenue to justify the investment. Investors should monitor whether the company can improve its capital efficiency as it shifts toward higher-margin streaming products, or if the current model is structurally incapable of generating positive economic value.

Working Capital Cycles Indicate Strain

According to quarterly filings, the company's cash conversion cycle reached 33 days in 2026Q1, reflecting a reliance on extended payment terms from sportsbook clients that complicates the firm's ability to manage the heavy, fixed-cost obligations inherent in its exclusive league data rights agreements.

The DSO of 87 days suggests that the company is effectively financing its sportsbook clients, which creates a mismatch between the timing of cash inflows and the rigid, non-cancellable payments owed to sports leagues. This working capital inefficiency appears to be a structural feature of the business model that limits liquidity during off-peak sporting seasons.

Seasonal Liquidity Requires Careful Monitoring

Based on the latest financial data, the current ratio of 1.59 provides a buffer for short-term obligations, yet the rapid decline in cash from 2025Q4 to 2026Q1 highlights a vulnerability to the seasonal cash outflows that characterize the company's rights-heavy operating model.

While the current ratio appears adequate on the surface, it masks the underlying volatility of cash flows that are heavily dependent on the global sports calendar. The company's liquidity position may be more fragile than the headline ratio suggests, particularly if the timing of league payments does not align perfectly with the receipt of sportsbook revenue shares.

Misapplication of EBITDA in Valuation

The most commonly misapplied metric for GENI is Adjusted EBITDA, which frequently obscures the company's true cash-generating potential by excluding significant stock-based compensation and the amortization of capitalized data rights that are essential to maintaining the firm's competitive position in the sports betting market.

Investors should instead focus on free cash flow and the 'rights value utilization' ratio to better understand the company's underlying performance. Relying on EBITDA allows the company to present a more favorable picture of profitability that ignores the reality of the massive, recurring cash outflows required to secure the exclusive data rights that underpin the entire business.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GENI — Frequently Asked Questions

Quick answers to the most common questions about buying GENI stock.

What is Genius Sports Limited's P/E ratio?

Genius Sports Limited's current P/E ratio is -14.7x. This places it at the 50th percentile of its historical range.

What is Genius Sports Limited's ROE?

Genius Sports Limited's return on equity (ROE) is -17.2%. The historical average is -37.7%.

Is GENI stock overvalued?

Based on historical data, Genius Sports Limited is trading at a P/E of -14.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Genius Sports Limited's profit margins?

Genius Sports Limited has 23.0% gross margin and -15.6% operating margin.